News and Announcements
EDITORIAL
Advances in Radiotherapy and Nuclear Medicine (ARNM): Leading the charge in oncological innovation
Tsair-Fwu Lee1,2,3*
Show Less
1
Medical Physics and Informatics Laboratory of Electronics Engineering, National Kaohsiung University of Science and Technology, Kaohsiung,
Taiwan
2
Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung,
Taiwan
3
Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung,
Taiwan
Submitted: 2 January 2024 | Published: 10 January 2024
![](https://article.accscience.com/imageFile/by.png)
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Conflict of interest
The author declares no conflict of interest.
References
- Levin-Epstein R, Cook RR, Wong JK, et al., 2020, Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol, 151: 26–32. https://doi.org/10.1016/j.radonc.2020.07.014
- Qi P, Chen Q, Tu D, et al., 2020, The potential role of borophene as a radiosensitizer in boron neutron capture therapy (BNCT) and particle therapy (PT). Biomater Sci, 8: 2778–2785. https://doi.org/10.1039/D0BM00318B
- Jhawar SR, Rivera-Núñez Z, Drachtman R, et al., 2019, Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma. JAMA Oncol, 5: 689–695. https://doi.org/10.1001/jamaoncol.2018.5911
- Sachpekidis C, Goldschmidt H, Dimitrakopoulou- Strauss A, 2019, Positron emission tomography (PET) radiopharmaceuticals in multiple myeloma. Molecules, 25: 134. https://doi.org/10.3390/molecules25010134
- Taïeb D, Jha A, Treglia G, et al., 2019, Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer, 26: R627–R652. https://doi.org/10.1530/ERC-19-0165